Linking Proteomic and Transcriptional Data through the Interactome and Epigenome Reveals a Map of Oncogene-induced Signaling
暂无分享,去创建一个
Ernest Fraenkel | Douglas A. Lauffenburger | William Gordon | David C. Clarke | Adam Labadorf | Sara J. C. Gosline | Shao-Shan Carol Huang | Candace R. Chouinard | D. C. Clarke | D. Lauffenburger | E. Fraenkel | S. Huang | W. Gordon | S. Gosline | Adam T. Labadorf | Sara J. C. Gosline | C. Chouinard
[1] D. Rubinsztein,et al. Huntington's disease: from pathology and genetics to potential therapies. , 2008, The Biochemical journal.
[2] William Stafford Noble,et al. Epigenetic priors for identifying active transcription factor binding sites , 2012, Bioinform..
[3] R. Derynck,et al. Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. , 2003, The Journal of biological chemistry.
[4] Jiang Shou,et al. Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.
[5] Gary D Bader,et al. PSICQUIC and PSISCORE: accessing and scoring molecular interactions , 2011, Nature Methods.
[6] Yan Ning,et al. The Constitutive Activity of Epidermal Growth Factor Receptor vIII Leads to Activation and Differential Trafficking of Wild-type Epidermal Growth Factor Receptor and erbB2 , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[7] Santosh Kesari,et al. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. , 2009, Neuro-oncology.
[8] Quan Tian,et al. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells , 2010, Investigational New Drugs.
[9] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[10] M. Selbach,et al. Global quantification of mammalian gene expression control , 2011, Nature.
[11] Koji Yoshimoto,et al. Primary Glioblastomas Express Mesenchymal Stem-Like Properties , 2006, Molecular Cancer Research.
[12] Douglas M. Bates,et al. Linear mixed model implementation in lme4 , 2013 .
[13] D. Karger,et al. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity , 2009, Nature Genetics.
[14] V. Tkach,et al. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility , 2004, International journal of cancer.
[15] Geoffrey C Kabat,et al. Do Steroid Hormones Play a Role in the Etiology of Glioma? , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[16] Frank Petersen,et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. , 2004, Cancer cell.
[17] Barrett C. Foat,et al. Profiling condition-specific, genome-wide regulation of mRNA stability in yeast. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[18] Rainer Spang,et al. Inferring cellular networks – a review , 2007, BMC Bioinformatics.
[19] Raymond K. Auerbach,et al. A User's Guide to the Encyclopedia of DNA Elements (ENCODE) , 2011, PLoS biology.
[20] Harmen J. Bussemaker,et al. TransfactomeDB: a resource for exploring the nucleotide sequence specificity and condition-specific regulatory activity of trans-acting factors , 2007, Nucleic Acids Res..
[21] Motoo Nagane,et al. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. , 2002, Cancer research.
[22] David J. Yang,et al. Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.
[23] Sheng-Chieh Hsu,et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.
[24] Y. Zhang,et al. IntAct—open source resource for molecular interaction data , 2006, Nucleic Acids Res..
[25] Cole Trapnell,et al. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.
[26] Nicola J. Rinaldi,et al. Transcriptional regulatory code of a eukaryotic genome , 2004, Nature.
[27] A. Rego,et al. Mechanisms of neurodegeneration in Huntington’s disease , 2008, European Journal of Neuroscience.
[28] Paul S Mischel,et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. , 2009, Cancer research.
[29] T. Lafortune,et al. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma , 2009, Molecular Cancer Therapeutics.
[30] H. Poulsen,et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[32] Matteo Fischetti,et al. An Algorithmic Framework for the Exact Solution of the Prize-Collecting Steiner Tree Problem , 2006, Math. Program..
[33] Clifford A. Meyer,et al. Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.
[34] R. Sharan,et al. Expander: from expression microarrays to networks and functions , 2010, Nature Protocols.
[35] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[36] Christopher J Schultz,et al. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. , 2006, Neuro-oncology.
[37] D. di Bernardo,et al. How to infer gene networks from expression profiles , 2007, Molecular systems biology.
[38] Alexander E. Kel,et al. TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes , 2005, Nucleic Acids Res..
[39] Lei Wang,et al. β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells , 2011, Medical oncology.
[40] Ronan M. T. Fleming,et al. Genome-Scale Reconstruction of Escherichia coli's Transcriptional and Translational Machinery: A Knowledge Base, Its Mathematical Formulation, and Its Functional Characterization , 2009, PLoS Comput. Biol..
[41] William Stafford Noble,et al. Global mapping of protein-DNA interactions in vivo by digital genomic footprinting , 2009, Nature Methods.
[42] Gordon K Smyth,et al. Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.
[43] V. Jordan,et al. Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? , 2009, Breast Cancer Research.
[44] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[45] Li Zhang,et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] David E Levy,et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. , 2008, Genes & development.
[47] M. Mann,et al. Defining the transcriptome and proteome in three functionally different human cell lines , 2010, Molecular systems biology.
[48] M. Mann,et al. Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.
[49] Samuel So,et al. Small molecule antagonists of Tcf4/β‐catenin complex inhibit the growth of HCC cells in vitro and in vivo , 2010, International journal of cancer.
[50] Keith L Black,et al. Suberoylanilide Hydroxamic Acid, a Histone Deacetylase Inhibitor: Effects on Gene Expression and Growth of Glioma Cells In vitro and In vivo , 2007, Clinical Cancer Research.
[51] J. Uhm,et al. The transcriptional network for mesenchymal transformation of brain tumours , 2010 .
[52] Caterina Giannini,et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Alexandre V. Morozov,et al. Statistical mechanical modeling of genome-wide transcription factor occupancy data by MatrixREDUCE , 2006, ISMB.
[54] Michael A. Thomas,et al. Integrating the Alzheimer's disease proteome and transcriptome: a comprehensive network model of a complex disease. , 2012, Omics : a journal of integrative biology.
[55] David A Potter,et al. Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity , 2008, Molecular Cancer Therapeutics.
[56] Huang Shao,et al. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. , 2003, Cancer research.
[57] Ting Wang,et al. An improved map of conserved regulatory sites for Saccharomyces cerevisiae , 2006, BMC Bioinformatics.
[58] E. Fraenkel,et al. Integrating Proteomic, Transcriptional, and Interactome Data Reveals Hidden Components of Signaling and Regulatory Networks , 2009, Science Signaling.
[59] E. Levin,et al. Integration of the extranuclear and nuclear actions of estrogen. , 2005, Molecular endocrinology.
[60] Xiaodong Jin,et al. Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations , 2011, Clinical and Experimental Medicine.
[61] Ernest Fraenkel,et al. Core transcriptional regulatory circuitry in human hepatocytes , 2006, Molecular systems biology.
[62] Geraldo Pereira Jotz,et al. Glutamate Promotes Cell Growth by EGFR Signaling on U-87MG Human Glioblastoma Cell Line , 2010, Pathology & Oncology Research.
[63] C. Klinge,et al. Estrogen receptor interaction with co-activators and co-repressors☆ , 2000, Steroids.
[64] Rory Stark. Differential Oestrogen Receptor Binding is Associated with Clinical Outcome in Breast Cancer , 2012, RECOMB.
[65] Kara Dolinski,et al. The BioGRID Interaction Database: 2011 update , 2010, Nucleic Acids Res..
[66] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[67] H. Wiley,et al. The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.
[68] Hugo Y. K. Lam,et al. Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.
[69] Y. Sakaki,et al. Phosphoproteome and transcriptome analyses of ErbB ligand-stimulated MCF-7 cells. , 2008, Cancer genomics & proteomics.
[70] Yanli Wang,et al. PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..
[71] David S. Lapointe,et al. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data , 2010, BMC Bioinformatics.
[72] Michael Platten,et al. Pathway inhibition: emerging molecular targets for treating glioblastoma. , 2011, Neuro-oncology.
[73] M. Stratton,et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.
[74] Gary D Bader,et al. BIND--The Biomolecular Interaction Network Database. , 2001, Nucleic acids research.
[75] Zohar Yakhini,et al. Discovering Motifs in Ranked Lists of DNA Sequences , 2007, PLoS Comput. Biol..
[76] W. Cavenee,et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[77] Rudolf Fahlbusch,et al. Suberoylanilide hydroxamic acid (SAHA) has potent anti‐glioma properties in vitro, ex vivo and in vivo , 2005, Journal of neurochemistry.
[78] Kimmo J Hatanpaa,et al. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. , 2006, Cancer research.
[79] Yanghua Xiao,et al. Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma , 2010, BMC Systems Biology.
[80] Alexander E. Kel,et al. MATCHTM: a tool for searching transcription factor binding sites in DNA sequences , 2003, Nucleic Acids Res..
[81] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[82] Takahiro Takano,et al. Glutamate release promotes growth of malignant gliomas , 2001, Nature Medicine.
[83] Paul S Mischel,et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis , 2009, Proceedings of the National Academy of Sciences.
[84] William Stafford Noble,et al. Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays , 2006, Nature Methods.
[85] Wenyan Lu,et al. Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. , 2009, European journal of pharmacology.
[86] Daniel Rios,et al. Ensembl 2011 , 2010, Nucleic Acids Res..
[87] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[88] Livia Perfetto,et al. MINT, the molecular interaction database: 2009 update , 2009, Nucleic Acids Res..
[89] Raghu Kalluri,et al. The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.
[90] Hong Ma,et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[91] A. Barthel,et al. Molecular mechanisms of insulin resistance , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[92] A. Wolffe,et al. p300 stimulates transcription instigated by ligand‐bound thyroid hormone receptor at a step subsequent to chromatin disruption , 1999, The EMBO journal.
[93] Ian M. Donaldson,et al. iRefIndex: A consolidated protein interaction database with provenance , 2008, BMC Bioinformatics.
[94] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[95] Frank Petersen,et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .
[96] Ki-Bum Lee,et al. Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. , 2011, Molecular pharmaceutics.
[97] Brian J. Bennett,et al. Comparative Analysis of Proteome and Transcriptome Variation in Mouse , 2011, PLoS genetics.
[98] J. Direnzo,et al. p300 is a component of an estrogen receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[99] Barry Merriman,et al. U87MG Decoded: The Genomic Sequence of a Cytogenetically Aberrant Human Cancer Cell Line , 2010, PLoS genetics.
[100] Sandhya Rani,et al. Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..
[101] Forest M White,et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.
[102] Michael A. Vogelbaum,et al. p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation , 2010, Oncotarget.
[103] J R Feramisco,et al. Enhanced Tumorigenic Behavior of Glioblastoma Cells Expressing a Truncated Epidermal Growth Factor Receptor Is Mediated through the Ras-Shc-Grb2 Pathway* , 1996, The Journal of Biological Chemistry.
[104] Bruce Mickey,et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. , 2009, Cancer research.
[105] Gordon K. Smyth,et al. limma: Linear Models for Microarray Data , 2005 .
[106] Nader Sanai,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma. , 2010, World neurosurgery.
[107] J. Streibig,et al. Bioassay analysis using R , 2005 .
[108] Mark J. Bowser,et al. EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes. , 2004, American journal of physiology. Gastrointestinal and liver physiology.
[109] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[110] E. Wingender,et al. MATCH: A tool for searching transcription factor binding sites in DNA sequences. , 2003, Nucleic acids research.
[111] Ernest Fraenkel,et al. Unbiased, Genome-Wide In Vivo Mapping of Transcriptional Regulatory Elements Reveals Sex Differences in Chromatin Structure Associated with Sex-Specific Liver Gene Expression , 2010, Molecular and Cellular Biology.
[112] Zihai Li,et al. 17 AAG for HSP90 inhibition in cancer--from bench to bedside. , 2009, Current molecular medicine.
[113] M L Apuzzo,et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[114] Forest M White,et al. Molecular Characterization of EGFR and EGFRvIII Signaling Networks in Human Glioblastoma Tumor Xenografts* , 2012, Molecular & Cellular Proteomics.
[115] Jacob F. Degner,et al. Sequence and Chromatin Accessibility Data Accurate Inference of Transcription Factor Binding from Dna Material Supplemental Open Access , 2022 .
[116] Eunjee Lee,et al. Identifying the genetic determinants of transcription factor activity , 2010, Molecular systems biology.
[117] S. Vandenberg,et al. EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway , 2012, Oncogene.
[118] A Guha,et al. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.
[119] J. Hassell,et al. Small Molecule Antagonists of the Wnt/Beta-Catenin Signaling Pathway Target Breast Tumor-Initiating Cells in a Her2/Neu Mouse Model of Breast Cancer , 2012, PloS one.
[120] Maria Sjöberg,et al. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. , 2005, Molecular endocrinology.
[121] H. Jiang,et al. Downregulation of Wnt2 and β-catenin by siRNA suppresses malignant glioma cell growth , 2009, Cancer Gene Therapy.
[122] Rafael A. Irizarry,et al. A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .
[123] Ernest Fraenkel,et al. ResponseNet: revealing signaling and regulatory networks linking genetic and transcriptomic screening data , 2011, Nucleic Acids Res..
[124] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[125] Yan Ning,et al. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. , 2005, Cancer research.
[126] J. Davis. Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .